Contrast-enhanced MR imaging of brain lesions: A large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide

Howard A. Rowley, G. Scialfa, P. Y. Gao, J. A. Maldjian, D. Hassell, M. J. Kuhn, F. J. Wippold, M. Gallucci, B. C. Bowen, I. M. Schmalfuss, J. Ruscalleda, S. Bastianello, C. Colosimo

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND PURPOSE: The higher relaxivity of gadobenate dimeglumine compared with gadodiamide is potentially advantageous for contrast-enhanced brain MR imaging. This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative lesion enhancement. MATERIALS AND METHODS: Adult patients with suggested or known brain lesions underwent 2 identical MR imaging examinations at 1.5T, one with gadobenate dimeglumine and the other with gadodiamide. The agents were administered in randomized order separated by 3-14 days. Imaging sequences and postinjection acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, and global preference) and quantitatively for contrast-to-noise ratio (CNR). RESULTS: One hundred thirteen of 138 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumor, metastasis, extra-axial tumor, or other (47, 27, 18, and 21 subjects, respectively). Readers 1, 2, and 3 demonstrated global preference for gadobenate dimeglumine in 63 (55.8%), 77 (68.1%), and 73 (64.6%) patients, respectively, compared with 3, 2, and 3 patients for gadodiamide (P <.0001, all readers). Highly significant (P <.0001, all readers) preference for gadobenate dimeglumine was demonstrated for all qualitative end points and for CNR (increases of 23.3%-34.7% and 42.4%-48.9% [spin-echo and gradient-refocused echo sequences, respectively] for gadobenate dimeglumine compared with gadodiamide). Inter-reader agreement was good for all evaluations (κ = 0.47-0.69). Significant preference for gadobenate dimeglumine was demonstrated for all lesion subgroup analyses. CONCLUSION: Significantly greater diagnostic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadodiamide at an equivalent dose.

Original languageEnglish
Pages (from-to)1684-1691
Number of pages8
JournalAmerican Journal of Neuroradiology
Volume29
Issue number9
DOIs
Publication statusPublished - Oct 2008

Fingerprint

gadodiamide
Neuroimaging
Noise
gadobenic acid
Neoplasms

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging

Cite this

Contrast-enhanced MR imaging of brain lesions : A large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. / Rowley, Howard A.; Scialfa, G.; Gao, P. Y.; Maldjian, J. A.; Hassell, D.; Kuhn, M. J.; Wippold, F. J.; Gallucci, M.; Bowen, B. C.; Schmalfuss, I. M.; Ruscalleda, J.; Bastianello, S.; Colosimo, C.

In: American Journal of Neuroradiology, Vol. 29, No. 9, 10.2008, p. 1684-1691.

Research output: Contribution to journalArticle

Rowley, HA, Scialfa, G, Gao, PY, Maldjian, JA, Hassell, D, Kuhn, MJ, Wippold, FJ, Gallucci, M, Bowen, BC, Schmalfuss, IM, Ruscalleda, J, Bastianello, S & Colosimo, C 2008, 'Contrast-enhanced MR imaging of brain lesions: A large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide', American Journal of Neuroradiology, vol. 29, no. 9, pp. 1684-1691. https://doi.org/10.3174/ajnr.A1185
Rowley, Howard A. ; Scialfa, G. ; Gao, P. Y. ; Maldjian, J. A. ; Hassell, D. ; Kuhn, M. J. ; Wippold, F. J. ; Gallucci, M. ; Bowen, B. C. ; Schmalfuss, I. M. ; Ruscalleda, J. ; Bastianello, S. ; Colosimo, C. / Contrast-enhanced MR imaging of brain lesions : A large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. In: American Journal of Neuroradiology. 2008 ; Vol. 29, No. 9. pp. 1684-1691.
@article{0381ada133214890822c05a86da30ef7,
title = "Contrast-enhanced MR imaging of brain lesions: A large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide",
abstract = "BACKGROUND AND PURPOSE: The higher relaxivity of gadobenate dimeglumine compared with gadodiamide is potentially advantageous for contrast-enhanced brain MR imaging. This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative lesion enhancement. MATERIALS AND METHODS: Adult patients with suggested or known brain lesions underwent 2 identical MR imaging examinations at 1.5T, one with gadobenate dimeglumine and the other with gadodiamide. The agents were administered in randomized order separated by 3-14 days. Imaging sequences and postinjection acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, and global preference) and quantitatively for contrast-to-noise ratio (CNR). RESULTS: One hundred thirteen of 138 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumor, metastasis, extra-axial tumor, or other (47, 27, 18, and 21 subjects, respectively). Readers 1, 2, and 3 demonstrated global preference for gadobenate dimeglumine in 63 (55.8{\%}), 77 (68.1{\%}), and 73 (64.6{\%}) patients, respectively, compared with 3, 2, and 3 patients for gadodiamide (P <.0001, all readers). Highly significant (P <.0001, all readers) preference for gadobenate dimeglumine was demonstrated for all qualitative end points and for CNR (increases of 23.3{\%}-34.7{\%} and 42.4{\%}-48.9{\%} [spin-echo and gradient-refocused echo sequences, respectively] for gadobenate dimeglumine compared with gadodiamide). Inter-reader agreement was good for all evaluations (κ = 0.47-0.69). Significant preference for gadobenate dimeglumine was demonstrated for all lesion subgroup analyses. CONCLUSION: Significantly greater diagnostic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadodiamide at an equivalent dose.",
author = "Rowley, {Howard A.} and G. Scialfa and Gao, {P. Y.} and Maldjian, {J. A.} and D. Hassell and Kuhn, {M. J.} and Wippold, {F. J.} and M. Gallucci and Bowen, {B. C.} and Schmalfuss, {I. M.} and J. Ruscalleda and S. Bastianello and C. Colosimo",
year = "2008",
month = "10",
doi = "10.3174/ajnr.A1185",
language = "English",
volume = "29",
pages = "1684--1691",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "9",

}

TY - JOUR

T1 - Contrast-enhanced MR imaging of brain lesions

T2 - A large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide

AU - Rowley, Howard A.

AU - Scialfa, G.

AU - Gao, P. Y.

AU - Maldjian, J. A.

AU - Hassell, D.

AU - Kuhn, M. J.

AU - Wippold, F. J.

AU - Gallucci, M.

AU - Bowen, B. C.

AU - Schmalfuss, I. M.

AU - Ruscalleda, J.

AU - Bastianello, S.

AU - Colosimo, C.

PY - 2008/10

Y1 - 2008/10

N2 - BACKGROUND AND PURPOSE: The higher relaxivity of gadobenate dimeglumine compared with gadodiamide is potentially advantageous for contrast-enhanced brain MR imaging. This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative lesion enhancement. MATERIALS AND METHODS: Adult patients with suggested or known brain lesions underwent 2 identical MR imaging examinations at 1.5T, one with gadobenate dimeglumine and the other with gadodiamide. The agents were administered in randomized order separated by 3-14 days. Imaging sequences and postinjection acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, and global preference) and quantitatively for contrast-to-noise ratio (CNR). RESULTS: One hundred thirteen of 138 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumor, metastasis, extra-axial tumor, or other (47, 27, 18, and 21 subjects, respectively). Readers 1, 2, and 3 demonstrated global preference for gadobenate dimeglumine in 63 (55.8%), 77 (68.1%), and 73 (64.6%) patients, respectively, compared with 3, 2, and 3 patients for gadodiamide (P <.0001, all readers). Highly significant (P <.0001, all readers) preference for gadobenate dimeglumine was demonstrated for all qualitative end points and for CNR (increases of 23.3%-34.7% and 42.4%-48.9% [spin-echo and gradient-refocused echo sequences, respectively] for gadobenate dimeglumine compared with gadodiamide). Inter-reader agreement was good for all evaluations (κ = 0.47-0.69). Significant preference for gadobenate dimeglumine was demonstrated for all lesion subgroup analyses. CONCLUSION: Significantly greater diagnostic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadodiamide at an equivalent dose.

AB - BACKGROUND AND PURPOSE: The higher relaxivity of gadobenate dimeglumine compared with gadodiamide is potentially advantageous for contrast-enhanced brain MR imaging. This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative lesion enhancement. MATERIALS AND METHODS: Adult patients with suggested or known brain lesions underwent 2 identical MR imaging examinations at 1.5T, one with gadobenate dimeglumine and the other with gadodiamide. The agents were administered in randomized order separated by 3-14 days. Imaging sequences and postinjection acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, and global preference) and quantitatively for contrast-to-noise ratio (CNR). RESULTS: One hundred thirteen of 138 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumor, metastasis, extra-axial tumor, or other (47, 27, 18, and 21 subjects, respectively). Readers 1, 2, and 3 demonstrated global preference for gadobenate dimeglumine in 63 (55.8%), 77 (68.1%), and 73 (64.6%) patients, respectively, compared with 3, 2, and 3 patients for gadodiamide (P <.0001, all readers). Highly significant (P <.0001, all readers) preference for gadobenate dimeglumine was demonstrated for all qualitative end points and for CNR (increases of 23.3%-34.7% and 42.4%-48.9% [spin-echo and gradient-refocused echo sequences, respectively] for gadobenate dimeglumine compared with gadodiamide). Inter-reader agreement was good for all evaluations (κ = 0.47-0.69). Significant preference for gadobenate dimeglumine was demonstrated for all lesion subgroup analyses. CONCLUSION: Significantly greater diagnostic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadodiamide at an equivalent dose.

UR - http://www.scopus.com/inward/record.url?scp=54249151048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54249151048&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A1185

DO - 10.3174/ajnr.A1185

M3 - Article

C2 - 18599575

AN - SCOPUS:54249151048

VL - 29

SP - 1684

EP - 1691

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 9

ER -